{"product_id":"chemed-swot-analysis","title":"Chemed SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Strategic Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eChemed shows resilient growth from Home Health Services and a defensive niche in hospice care, but reimbursement exposure and labor costs pose tangible risks; our full SWOT unpacks competitive moats, regulatory pressures, and acquisition implications. Purchase the complete SWOT to receive a professionally formatted, editable Word and Excel package with actionable insights for investors and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Leadership in Hospice Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVITAS Healthcare, Chemed’s hospice unit, is the largest US end-of-life provider, serving about 70,000 patients annually in 43 states as of 2024, giving Chemed scale-based cost advantages and stronger vendor negotiation power.\u003c\/p\u003e\n\u003cp\u003eThat scale supports specialized clinical infrastructure and care pathways smaller regional hospices lack, improving quality and margin stability; referrals from 1,200+ hospital and health system partners fuel steady admissions and revenue visibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecession-Resistant Business Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe dual-segment structure—VITAS hospice and Roto-Rooter plumbing—combines essential healthcare with emergency residential services, giving steady demand across cycles; in 2024 VITAS delivered ~$1.7B revenue and Roto-Rooter ~$1.3B, together ~55% of Chemed’s $2.9B total.\u003c\/p\u003e\n\u003cp\u003eHospice care is largely non-discretionary—Medicare covers ~80% of U.S. hospice patient days—while plumbing\/water restoration are urgent services consumers defer rarely, helping stabilize margins and cash flow during downturns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Brand Equity of Roto-Rooter\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoto-Rooter is the most recognized name in North American plumbing, driving customer acquisition across ~600 company-operated and franchise locations; brand strength supports premium pricing and boosted loyalty, helping Chemed report 2024 segment margins above peers (company plumbing margins ~18–20% vs industry avg ~12–15%).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Cash Flow and Financial Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChemed generates strong free cash flow—$622 million in fiscal 2024—enabling disciplined capital allocation toward share buybacks and consecutive dividend increases through 2025.\u003c\/p\u003e\n\u003cp\u003eAs of Q3 2025 the company shows a conservative net debt\/EBITDA around 1.1x, supporting internal investments and selective M\u0026amp;A without straining liquidity.\u003c\/p\u003e\n\u003cp\u003eThis financial stability differentiates Chemed for long-term investors focused on value and capital preservation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFree cash flow: $622M (FY2024)\u003c\/li\u003e\n\u003cli\u003eNet debt\/EBITDA: ~1.1x (Q3 2025)\u003c\/li\u003e\n\u003cli\u003eOngoing buybacks + annual dividend growth through 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Efficiency through Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChemed has integrated proprietary dispatch software in Roto-Rooter, cutting average dispatch-to-arrival times and boosting technician productivity; Roto-Rooter sales per tech rose ~6% in 2024, lifting segment margins. \u003c\/p\u003e\n\u003cp\u003eVITAS uses advanced electronic health records to speed documentation and ensure Medicare compliance, reducing admin costs—VITAS SG\u0026amp;A margin fell ~1.2 percentage points in FY2024. \u003c\/p\u003e\n\u003cp\u003eThese tech investments jointly improve service quality and drove a ~150 bps gross margin expansion company-wide in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRoto-Rooter: +6% sales per tech (2024)\u003c\/li\u003e\n\u003cli\u003eVITAS: –1.2 pp SG\u0026amp;A margin (FY2024)\u003c\/li\u003e\n\u003cli\u003eCompany: +150 bps gross margin (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChemed: $3B scale, $622M FCF, low leverage and tech-driven margin gains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChemed’s scale: VITAS serves ~70,000 patients across 43 states (2024) and Roto-Rooter operates ~600 locations; combined 2024 revenue ~$3.0B (VITAS ~$1.7B; Roto-Rooter ~$1.3B). Strong cash flow: FCF $622M (FY2024); net debt\/EBITDA ~1.1x (Q3 2025). Tech boosts: Roto-Rooter +6% sales\/tech (2024); VITAS SG\u0026amp;A −1.2pp (2024); company gross margin +150bps (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVITAS patients\u003c\/td\u003e\n\u003ctd\u003e~70,000 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e~$3.0B total\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFCF\u003c\/td\u003e\n\u003ctd\u003e$622M (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\/EBITDA\u003c\/td\u003e\n\u003ctd\u003e~1.1x (Q3 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExamines the opportunities and risks shaping the future of Chemed by outlining its core strengths and weaknesses alongside external market drivers and competitive threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise Chemed SWOT summary for rapid strategic alignment, ideal for executives and analysts needing a clear snapshot of strengths, weaknesses, opportunities, and threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Reliance on Medicare Reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA substantial portion of VITAS Healthcare revenue—about 70% of hospice receipts in 2024—comes from Medicare and Medicaid, creating concentration risk tied to federal policy.\u003c\/p\u003e\n\u003cp\u003eAny cut to the 2025 Medicare hospice aggregate rate or changes to benefit rules could reduce hospice margins—VITAS reported 15% operating margin in FY2024—almost immediately.\u003c\/p\u003e\n\u003cp\u003eThis reliance requires active monitoring of Washington D.C. policy debates, CMS rulemaking, and Congressional funding actions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor Intensive Operational Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpboth chemed two segments depend on large pools of specialized staff nurses and licensed therapists in vitas hospice home health skilled plumbers at roto-rooter a labor-intensive model that drove labor costs up year-over-year for healthcare trade wages rose nationally. if pricing fails to match inflation cpi margin pressure follows operating could compress further. managing decentralized workforce across locations hundreds sites raises scheduling compliance recruitment increasing turnover risk capital tied training.\u003e\n\u003c\/pboth\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSegment Divergence and Complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp the lack of operational synergy between chemed hospice arm healthcare revenue and roto-rooter likely creates a conglomerate discount as investors struggle to apply unified multiples vs. home-services cash flows. analysts flagged harder valuation: median ev for peers plumbing in widening appraisal gaps. this structural complexity can distract executives raising integration capital-allocation opportunity costs.\u003e\n\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSusceptibility to Skilled Labor Shortages\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eChemed struggles to recruit and retain nurses and plumbers amid industry shortages; hospice turnover exceeded 35% in 2024, driving higher hiring costs and lower margins for VITAS and Roto-Rooter.\u003c\/p\u003e\n\u003cp\u003eStaffing gaps forced capacity cuts in several markets in 2024, capping revenue growth where patient admissions or service calls exceeded available staff.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHospice turnover ~35% (2024)\u003c\/li\u003e\n\u003cli\u003eRecruitment costs up, margin pressure\u003c\/li\u003e\n\u003cli\u003eSome markets capped capacity in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Audit Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOperating in healthcare exposes Chemed to strict federal scrutiny over billing and clinical eligibility; CMS and OIG audits of hospice and vascular services can trigger costly reviews—Chemed paid $16.8m in legal\/settlement expenses in 2023, showing scale of risk.\u003c\/p\u003e\n\u003cp\u003eFrequent audits and Medicare claim disputes can produce large legal fees or penalties, and contested findings could hit revenue and margins; audit cycles lengthen cash-flow timing.\u003c\/p\u003e\n\u003cp\u003eRigorous documentation requirements add heavy admin costs and slow ops; RHYTHM Hospice reported 12% higher admin hours per patient in 2024, a proxy for sector burden.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2023 legal\/settlement costs: $16.8m\u003c\/li\u003e\n\u003cli\u003eHigh audit frequency → slower cash collections\u003c\/li\u003e\n\u003cli\u003eDocumentation burden raises admin hours ≈12%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChemed risk: Medicare reliance, rising labor\/legal costs and potential valuation drag\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh Medicare\/Medicaid dependence (~70% hospice revenue, FY2024) and exposure to CMS rule changes threaten VITAS margins (15% operating margin, FY2024); labor shortages and wage inflation raised costs ~6–8% in 2024, squeezing Chemed’s consolidated margin (~9% in 2024); regulatory audits drove $16.8m legal\/settlement costs in 2023 and increase admin burden (~12% more hours per patient), while conglomerate structure and divergent EV\/EBITDA multiples (hospice ~12x vs plumbing ~8x, 2024) risk a valuation discount.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (Year)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospice % Medicare\/Medicaid\u003c\/td\u003e\n\u003ctd\u003e~70% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVITAS operating margin\u003c\/td\u003e\n\u003ctd\u003e15% (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChemed consolidated margin\u003c\/td\u003e\n\u003ctd\u003e~9% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabor cost rise (healthcare)\u003c\/td\u003e\n\u003ctd\u003e~6–8% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdmin hours per patient (proxy)\u003c\/td\u003e\n\u003ctd\u003e+12% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegal\/settlement costs\u003c\/td\u003e\n\u003ctd\u003e$16.8m (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEV\/EBITDA hospice vs plumbing\u003c\/td\u003e\n\u003ctd\u003e~12x vs ~8x (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eChemed SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Chemed SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report; buy now to unlock the complete, editable version with in-depth strengths, weaknesses, opportunities, and threats tailored to Chemed’s business and market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752578920825,"sku":"chemed-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/chemed-swot-analysis.png?v=1772242589","url":"https:\/\/matrixbcg.com\/products\/chemed-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}